Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with delayed rituximab and optional ibrutinib consolidation for first-line CLL aiming at undetectable MRD
2020-004409-30Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, rituximab and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by IRCCS Ospedale San Raffaele. Started Aug 2021; status: active.
02
Drugs
venetoclaxrituximabibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2020-004409-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004409-30.